Form 4: Xilio Therapeutics Director Paul Clancy Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director Paul J. Clancy was granted 31,000 stock options with an exercise price of $0.693, vesting over the next year, as reported in a recent SEC Form 4 filing.

Summary

• Paul J. Clancy, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options.
• The options have an exercise price of $0.693 per share.
• The grant date for these options was June 11, 2025.
• The options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date, contingent on Mr. Clancy's continued service.
• The options expire on June 10, 2035.
• Following this transaction, Mr. Clancy directly beneficially owns 31,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued commitment and aligns management's interests with long-term shareholder value, though it is a routine compensation event rather than a strategic business announcement.

Positives

• The grant of 31,000 stock options to Director Paul J. Clancy aligns his interests with long-term shareholder value, as the options vest subject to his continued service.
• The options have a long expiration date of June 10, 2035, providing a significant window for potential value realization.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an equity grant.

Risks

• No specific risks are detailed within this Form 4 filing, which focuses solely on the grant of stock options.

Future Outlook

The options are set to vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, contingent on the Director's continued service.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing details a specific insider equity grant and does not provide sufficient information for a comparison to industry-wide compensation standards or company performance benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The reported transaction is an equity grant from the Issuer to a Director, which is a standard related-party compensation arrangement. No other unusual related party transactions are disclosed.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with shareholder value.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

Xilio Therapeutics, XLO, Paul Clancy, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity grant